ClinicalTrials.gg
RecruitingNCT06142019Updated Oct 14, 2026

Pulse Oximeter Accuracy in Healthy Humans During Hypoxia

An observational study in Hypoxia and Skin Pigmentation, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by University of California, San Francisco · Observational

From the registry’s dates

  • Started Nov 2021; still recruiting 4 years 11 months later.
Updated Oct 14, 2026Study contact changedGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The aim of this project is to test the accuracy of pulse oximeters during mild, moderate and severe hypoxia. This is done by comparing the reading of the pulse oximeter during brief, steady state hypoxia with a gold-standard measurement of blood oxygen. This study will be done on healthy male or females between the age group of 18-50.

Read the detailed description

This study is to determine the accuracy of pulse oximeters, which measure blood oxygen by shining light through fingers, ears or other parts of the body, without requiring blood sampling.

The aim of this project is to test the accuracy of pulse oximeters during mild, moderate and severe hypoxia. This is done by comparing the reading of the pulse oximeter during brief, steady state hypoxia with a gold-standard measurement of blood oxyhemoglobin saturation (arterial blood sample processed in a laboratory hemoximeter).The data obtained is submitted by pulse oximeter manufacturers to the FDA for device approval.

Studies normally involve 10-14 normal adult volunteer paid subjects, with 20-25 1-2 ml arterial blood samples from each subject obtained at different steady-state levels of hypoxia from 70-100%. Blood samples obtained from an arterial line are measured in a hemoximeter to determine true saturation value. Some sponsors may not require any blood sampling. Some sponsors may require additional blood samples, up to 35 samples may be drawn. Readings from the test pulse oximeters are recorded and compared to these "gold-standard" blood values. The pulse oximeter probes may be located at a variety of sites on the subjects, including fingers, toes, ears, forehead, scalp and bridge of the nose. These detector-probes are all non-invasive.

The level of hypoxia is measured and controlled by the investigator. A computer program that displays a prediction, breath by breath, the arterial oxygen saturation, (SaO2) of the study subject. SaO2 is computed from end-expired Po2 and Pco2 as determined by mass spectrometer gas analysis. This information permits the inspired gas mixture of air, plus CO2 and nitrogen, to be adjusted by an operator watching the value computed after each expiration on an analog meter. This computer-estimated saturation is adjusted by the operator to one of 6 levels of predicted saturation, and is held stable for about 30 seconds at each level. Two or three "runs" are conducted per subject. Each "run" lasts 10-15 min and 4 to 5 plateaus are tested per run. The manufacturer may choose the target values. Plateaus are typically sought at 96%, 87%, 77%, 92%, 82% and 72%. Other manufacturers have asked for an equal number of data points but with all points between 70% and 100%. Some sponsors may also request additional variables to be measured during testing including high or low CO2, where subjects will be asked to hyperventilate; low perfusion, where subjects will be asked to lay flat, or with their head up or down; testing pulse oximeters during motion, or with the subject's hand fixed to a motion machine. The subject's will be informed by the study staff and in the consent form if any of these additional procedures apply.

02

Conditions studied

  • Hypoxia
  • Skin Pigmentation
03

In context

Hypoxia

1,076 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 79 across 277 observational studies indexed under Hypoxia.

Browse Hypoxia studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,169 studies on the registry; 372 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 202 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Study population consists of healthy volunteers between 18-50 years of age across all ethnic and racial backgrounds.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is male or female, aged ≥18 and \<50.
  2. The subject is in good general health with no evidence of any medical problems.
  3. The subject is fluent in both written and spoken English.
  4. The subject has provided and is willing to comply with the study procedures.

Exclusion criteria

Exclusion Criteria:

  1. The subject is obese (>35).
  2. The subject has a known history of heart disease, lung disease, kidney or liver disease.
  3. Diagnosis of asthma, sleep apnea, or use of CPAP.
  4. Subject has diabetes.
  5. Subject has a clotting disorder.
  6. The subject a hemoglobinopathy or history of anemia, per subject report or the first blood sample, that in the opinion of the investigator, would make them unsuitable for study participation.
  7. The subject has any other serious systemic illness.
  8. The subject is a current smoker.
  9. Any injury, deformity, or abnormality at the sensor sites that in the opinion of the investigators' would interfere with the sensors working correctly.
  10. The subject has a history of fainting or vasovagal response.
  11. The subject has a history of sensitivity to local anesthesia.
  12. The subject has a diagnosis of Raynaud's disease.
  13. The subject has unacceptable collateral circulation based on exam by the investigator (Allen's test).
  14. The subject is pregnant, lactating or trying to get pregnant.
  15. The subject is unable or unwilling to provide , or is unable or unwilling to comply with study procedures.
  16. The subject has any other condition, which in the opinion of the investigators' would make them unsuitable for the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Interventions

  • DeviceControlled desaturation (hypoxemia)

    Stable hypoxemia is created in healthy subjects by having them breathe hypoxic air mixtures

06

What researchers measure

Primary outcomes

  1. SpO2

    Reading on pulse oximeter device which is an estimate of the patient's blood oxygen level.

    Time frame: 08/01/2025

Secondary outcomes

  1. Blood gas SO2

    Arterial blood gas sample results showing exact SpO2 levels. SpO2 ranges from 1% to 100%. Our target SpO2 levels are between 67% and 100%.

    Time frame: 08/01/2025

  2. Skin Pigmentation by ITA

    ITA stands for individual typology angle from a spectrophotometer which is an objective measurement of skin pigmentation. The categories for the ITA scale are the following: \> 55 Very Light, 41 to 55 Light, 28 to 41 Intermediate, 10 to 28 Tan, -30 to 10 Brown, \< -30 Dark.

    Time frame: 08/01/2025

  3. Finger Diameter

    Finger diameter is measured to ensure that the pulse oximeters being tested work with a variety of finger sizes. Finger diameter is measured in mm.

    Time frame: 08/01/2025

  4. Skin Pigmentation by Monk Scale

    The Monk scale is a subjective categorization of skin pigmentation. The Monk Scale is a 10 shade scale designed to to be easy-to-use for development and evaluation of technology while presenting a more representative range of skin tones than other common qualitative scales. The Monk Scale is from A to J. A being the lightest skin color and J the darkest.

    Time frame: 08/01/2025

07

Study locations

1 of 1 sites recruiting
  • Hypoxia Lab, UCSF Department of Anesthesia and Perioperative Care
    San Francisco, California 94143, United States
    Recruiting
08

References and documents

Publications

  • Feiner JR, Bickler PE, Mannheimer PD. Accuracy of methemoglobin detection by pulse CO-oximetry during hypoxia. Anesth Analg. 2010 Jul;111(1):143-8. doi: 10.1213/ANE.0b013e3181c91bb6. Epub 2009 Dec 10. PubMed 20007731 ↗
  • Feiner JR, Severinghaus JW, Bickler PE. Dark skin decreases the accuracy of pulse oximeters at low oxygen saturation: the effects of oximeter probe type and gender. Anesth Analg. 2007 Dec;105(6 Suppl):S18-S23. doi: 10.1213/01.ane.0000285988.35174.d9. PubMed 18048893 ↗
  • Bickler PE, Feiner JR, Severinghaus JW. Effects of skin pigmentation on pulse oximeter accuracy at low saturation. Anesthesiology. 2005 Apr;102(4):715-9. doi: 10.1097/00000542-200504000-00004. PubMed 15791098 ↗

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Contact
Study contact changed: P•••@ucsf.edu · •••1411→e•••@ucsf.edu · •••4285. See the current contact
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Contact Study contact changed: P•••@ucsf.edu · •••1411→e•••@ucsf.edu · •••4285. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06142019
Responsible party
Sponsor
First posted
Nov 21, 2023
Start date
Nov 29, 2021
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Ella Behnke
Contact
ella.behnke@ucsf.edu
971-295-4285
Michael Lipnick, MD
Contact
Michael.lipnick@ucsf.edu
628-206-7736
Philip E Bickler, MD, PhD
principal investigator · University of California at San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion